KemPharm Inc. (KMPH) Lowered to “Hold” at Zacks Investment Research
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
KMPH has been the subject of a number of other reports. Oppenheimer Holdings Inc. reissued a buy rating and issued a $11.00 price target on shares of KemPharm in a report on Tuesday, June 14th. Canaccord Genuity reissued a buy rating on shares of KemPharm in a report on Wednesday, August 10th.
Shares of KemPharm (NASDAQ:KMPH) opened at 4.55 on Wednesday. KemPharm has a 12 month low of $3.52 and a 12 month high of $21.30. The company’s 50 day moving average is $4.62 and its 200-day moving average is $7.45. The company’s market cap is $66.64 million.
KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.36. Analysts expect that KemPharm will post ($1.78) EPS for the current fiscal year.
In related news, EVP Daniel L. Cohen acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, September 6th. The shares were purchased at an average price of $4.75 per share, with a total value of $47,500.00. Following the acquisition, the executive vice president now directly owns 1,310 shares in the company, valued at $6,222.50. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 22.80% of the company’s stock.
Large investors have recently modified their holdings of the company. Parkwood LLC bought a new stake in shares of KemPharm during the second quarter worth approximately $107,000. William Harris Investors Inc. raised its stake in shares of KemPharm by 93.3% in the second quarter. William Harris Investors Inc. now owns 30,891 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 14,911 shares in the last quarter. Menta Capital LLC raised its stake in shares of KemPharm by 11.3% in the first quarter. Menta Capital LLC now owns 11,410 shares of the specialty pharmaceutical company’s stock worth $165,000 after buying an additional 1,154 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of KemPharm by 4.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 35,485 shares of the specialty pharmaceutical company’s stock worth $515,000 after buying an additional 1,653 shares in the last quarter. Finally, Spark Investment Management LLC raised its stake in shares of KemPharm by 195.1% in the second quarter. Spark Investment Management LLC now owns 141,109 shares of the specialty pharmaceutical company’s stock worth $561,000 after buying an additional 93,284 shares in the last quarter. 42.65% of the stock is currently owned by hedge funds and other institutional investors.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Stock Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related stocks with our FREE daily email newsletter.